MDxHealth (NASDAQ:MDXH – Get Free Report) and Precipio (NASDAQ:PRPO – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.
Risk and Volatility
MDxHealth has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, Precipio has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500.
Insider & Institutional Ownership
10.5% of Precipio shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by company insiders. Comparatively, 16.9% of Precipio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MDxHealth | $90.05 million | 1.69 | -$38.07 million | ($0.64) | -5.02 |
| Precipio | $18.53 million | 2.19 | -$4.29 million | ($0.82) | -28.23 |
Precipio has lower revenue, but higher earnings than MDxHealth. Precipio is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for MDxHealth and Precipio, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MDxHealth | 1 | 0 | 4 | 0 | 2.60 |
| Precipio | 1 | 0 | 0 | 0 | 1.00 |
MDxHealth presently has a consensus target price of $7.75, indicating a potential upside of 141.43%. Given MDxHealth’s stronger consensus rating and higher possible upside, analysts plainly believe MDxHealth is more favorable than Precipio.
Profitability
This table compares MDxHealth and Precipio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MDxHealth | -30.50% | -1,078.01% | -20.05% |
| Precipio | -5.50% | -10.07% | -6.71% |
About MDxHealth
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
About Precipio
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.
